Theravance Biopharma (TBPH) Accounts Payables (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 54.32% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 54.32% decrease from a year earlier, with the FY2025 full-year figure at $2.6 million, up 14.54% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.1 million, down from $2.6 million in the prior quarter.
• Over the last five years, Accounts Payables for TBPH reached as high as $5.3 million in Q3 2022 and fell as low as $1.1 million in Q1 2026.
• Historically, Accounts Payables has averaged $2.2 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Accounts Payables sank 77.9% in 2022 and soared 76.36% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $1.6 million in 2022, then fell by 1.93% to $1.5 million in 2023, then soared by 47.11% to $2.2 million in 2024, then increased by 14.54% to $2.6 million in 2025, then slumped by 57.17% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $1.1 million in Q1 2026, $2.6 million in Q4 2025, and $2.2 million in Q3 2025.